Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.18 ^USD	+5.88%		+14.72%	+18.89%

Apr. 19	Venture Life renews revolving credit facility with Santander and HSBC	AN
Apr. 18	Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	CI

Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 06:04 am EDT

Jaguar Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 12.15 million compared to USD 9.37 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 8.77 a year ago.
For the six months, net loss was USD 24.35 million compared to USD 27.35 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 29.51 a year ago.

Latest news about Jaguar Health, Inc.

Venture Life renews revolving credit facility with Santander and HSBC	Apr. 19	AN
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	Apr. 18	CI
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	Apr. 10	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	Apr. 10	MT
Top Premarket Gainers	Apr. 10	MT
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International	Apr. 03	CI
Transcript : Jaguar Health, Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	Feb. 15	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	Feb. 15	CI
Top Premarket Gainers	Jan. 26	MT
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	Dec. 11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	Dec. 04	CI
Jaguar Health, Inc. announced that it has received $0.06 million in funding	Nov. 29	CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Nov. 21	MT
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall	Nov. 21	MT
Transcript : Jaguar Health, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : Jaguar Health, Inc. - Special Call	Nov. 08
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	Nov. 08	MT
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	Nov. 01	CI
Jaguar Health, Inc. announced that it expects to receive $0.06 million in funding	23-08-31	CI
Transcript : Jaguar Health, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q2 Revenue $2.7M	23-08-14	MT

Chart Jaguar Health, Inc.

Duration

Period

More charts

Company Profile

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
JAGUAR HEALTH, INC.	+18.89%	49.72M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs